99 related articles for article (PubMed ID: 20140759)
1. Cetuximab in combination therapy: from bench to clinic.
Gerber DE; Choy H
Cancer Metastasis Rev; 2010 Mar; 29(1):171-80. PubMed ID: 20140759
[TBL] [Abstract][Full Text] [Related]
2. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
Wong SF
Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
[TBL] [Abstract][Full Text] [Related]
3. Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximab.
Prewett M; Deevi DS; Bassi R; Fan F; Ellis LM; Hicklin DJ; Tonra JR
Clin Cancer Res; 2007 Dec; 13(24):7432-40. PubMed ID: 18094427
[TBL] [Abstract][Full Text] [Related]
4. The role of cetuximab in the therapy of previously treated advanced colorectal cancer.
Chong G; Cunningham D
Semin Oncol; 2005 Dec; 32(6 Suppl 9):S55-8. PubMed ID: 16399433
[TBL] [Abstract][Full Text] [Related]
5. Update on novel strategies to optimize cetuximab therapy in patients with metastatic colorectal cancer.
Macarulla T; Ramos FJ; Elez E; Capdevila J; Peralta S; Tabernero J
Clin Colorectal Cancer; 2008 Sep; 7(5):300-8. PubMed ID: 18794061
[TBL] [Abstract][Full Text] [Related]
6. Is there a role for cetuximab in non small cell lung cancer?
Morgensztern D; Govindan R
Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4602-5. PubMed ID: 17671149
[TBL] [Abstract][Full Text] [Related]
7. Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers.
Rosa R; Melisi D; Damiano V; Bianco R; Garofalo S; Gelardi T; Agrawal S; Di Nicolantonio F; Scarpa A; Bardelli A; Tortora G
Clin Cancer Res; 2011 Oct; 17(20):6531-41. PubMed ID: 21890455
[TBL] [Abstract][Full Text] [Related]
8. Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial.
Rivera F; García-Castaño A; Vega N; Vega-Villegas ME; Gutiérrez-Sanz L
Expert Rev Anticancer Ther; 2009 Oct; 9(10):1421-8. PubMed ID: 19828002
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy of metastatic colorectal cancer.
Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
[TBL] [Abstract][Full Text] [Related]
10. Cetuximab plus oxaliplatin-based chemotherapy in the treatment of colorectal cancer.
Moosmann N; Heinemann V
Expert Rev Anticancer Ther; 2008 Mar; 8(3):319-29. PubMed ID: 18366281
[TBL] [Abstract][Full Text] [Related]
11. The evolving role of cetuximab in non-small cell lung cancer.
Lilenbaum RC
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4432s-4435s. PubMed ID: 16857823
[TBL] [Abstract][Full Text] [Related]
12. The biological properties of cetuximab.
Vincenzi B; Schiavon G; Silletta M; Santini D; Tonini G
Crit Rev Oncol Hematol; 2008 Nov; 68(2):93-106. PubMed ID: 18676156
[TBL] [Abstract][Full Text] [Related]
13. In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR.
Balin-Gauthier D; Delord JP; Rochaix P; Mallard V; Thomas F; Hennebelle I; Bugat R; Canal P; Allal C
Cancer Chemother Pharmacol; 2006 Jun; 57(6):709-18. PubMed ID: 16320055
[TBL] [Abstract][Full Text] [Related]
14. Response to reintroduction of cetuximab in 5 patients with advanced, chemotherapy-resistant, colorectal cancer without progressive disease following first-line therapy with a cetuximab-containing regimen.
Kaechele V; von Wichert G; Adler G; Seufferlein T
Oncology; 2008; 74(3-4):123-6. PubMed ID: 18708729
[TBL] [Abstract][Full Text] [Related]
15. An update on treatment advances for the first-line therapy of metastatic colorectal cancer.
Lee JJ; Chu E
Cancer J; 2007; 13(5):276-81. PubMed ID: 17921724
[TBL] [Abstract][Full Text] [Related]
16. Targeted therapy in colorectal cancer.
Rajpal S; Venook AP
Clin Adv Hematol Oncol; 2006 Feb; 4(2):124-32. PubMed ID: 16728921
[TBL] [Abstract][Full Text] [Related]
17. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.
Bertotti A; Migliardi G; Galimi F; Sassi F; Torti D; Isella C; Corà D; Di Nicolantonio F; Buscarino M; Petti C; Ribero D; Russolillo N; Muratore A; Massucco P; Pisacane A; Molinaro L; Valtorta E; Sartore-Bianchi A; Risio M; Capussotti L; Gambacorta M; Siena S; Medico E; Sapino A; Marsoni S; Comoglio PM; Bardelli A; Trusolino L
Cancer Discov; 2011 Nov; 1(6):508-23. PubMed ID: 22586653
[TBL] [Abstract][Full Text] [Related]
18. Cetuximab in advanced non-small cell lung cancer.
Govindan R
Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4241s-4244s. PubMed ID: 15217966
[TBL] [Abstract][Full Text] [Related]
19. Cetuximab: new drug. Metastatic colorectal cancer: an inappropriate evaluation.
Prescrire Int; 2005 Dec; 14(80):215-7. PubMed ID: 16400742
[TBL] [Abstract][Full Text] [Related]
20. Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies.
Vermorken JB; Herbst RS; Leon X; Amellal N; Baselga J
Cancer; 2008 Jun; 112(12):2710-9. PubMed ID: 18481809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
